Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of “Hold” by Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $6.75.

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Finally, HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, December 30th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares in the last quarter. Bank of Montreal Can lifted its position in Inovio Pharmaceuticals by 23.7% during the second quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 11,110 shares in the last quarter. MCF Advisors LLC acquired a new position in Inovio Pharmaceuticals during the third quarter worth $26,000. SG Americas Securities LLC acquired a new position in Inovio Pharmaceuticals during the third quarter worth $27,000. Finally, Stephens Inc. AR purchased a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at $32,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Key Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright issues an optimistic outlook for INO’s Q1 results, which could support sentiment if the company posts stronger-than-expected metrics. HC Wainwright Has Optimistic Outlook of INO Q1 Earnings
• Neutral Sentiment: Investors can review Inovio’s Q4 2025 earnings call transcript for detail on recent results and management commentary that may affect forward guidance and cash runway. Q4 2025 earnings call transcript
• Negative Sentiment: Multiple law firms have publicized a securities class action against Inovio (class period: Oct 10, 2023–Dec 26, 2025) and are soliciting lead-plaintiff candidates ahead of an April 7, 2026 deadline — increasing the likelihood of continued legal overhang, litigation costs and distraction for management. Representative notices include Pomerantz and Rosen. Pomerantz class action filing
• Negative Sentiment: Several additional firms (Faruqi & Faruqi, The Gross Law Firm, Glancy Prongay Wolke, Bronstein Gewirtz & Grossman, Schall Law Firm) have issued shareholder alerts about the same litigation and the April 7 deadline, amplifying media attention and potential plaintiff coordination. Faruqi & Faruqi investor notice
• Negative Sentiment: Coverage in financial press flags alleged disclosure issues around Inovio’s vaccine candidates, which is the basis for the shareholder suit and could prompt regulatory scrutiny or increased reputational risk. Inovio faces shareholder lawsuit article

Inovio Pharmaceuticals Price Performance

Shares of Inovio Pharmaceuticals stock opened at $1.58 on Monday. The stock has a market capitalization of $109.16 million, a P/E ratio of -0.94 and a beta of 1.70. The business has a 50 day simple moving average of $1.65 and a two-hundred day simple moving average of $2.02. Inovio Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.68. The firm had revenue of ($0.07) million during the quarter, compared to analyst estimates of $0.33 million. As a group, research analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.